{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-enteropancreatic+Neuroendocrine+Tumor&page=2", "query": { "condition": "Gastro-enteropancreatic Neuroendocrine Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-enteropancreatic+Neuroendocrine+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T23:27:36.308Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04276597", "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Neuroendocrine Neoplasm", "Pheochromocytoma", "Paraganglioma", "Thymus Carcinoid", "Unknown Primary Tumors", "Neuroendocrine Tumors", "Neuroendocrine Skin Carcinoma", "Neuroendocrine Breast Tumor", "Neuroendocrine Carcinoma Metastatic", "Neuroendocrine Neoplasm of Ovary" ], "interventions": [ { "name": "177Lu-DOTATOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Excel Diagnostics and Nuclear Oncology Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-04", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276597" }, { "nct_id": "NCT03049189", "title": "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-edotreotide PRRT", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Amino-Acid Solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ITM Solucin GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2017-02-02", "completion_date": "2029-11", "has_results": true, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 6, "location_summary": "Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049189" }, { "nct_id": "NCT02611024", "title": "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Glioblastoma", "Soft Tissue Sarcoma (Excluding GIST)", "Endometrial Carcinoma", "Epithelial Ovarian Carcinoma", "Mesothelioma", "Gastroenteropancreatic Neuroendocrine Tumor", "SCLC", "Gastric Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Carcinoma", "Neuroendocrine Tumors" ], "interventions": [ { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2016-05-06", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 4, "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611024" }, { "nct_id": "NCT04609592", "title": "Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "Gallium 68 Dotatate", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "PET/CT", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-03-17", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04609592" }, { "nct_id": "NCT04505553", "title": "Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Carcinoma", "Colon Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Liver and Intrahepatic Bile Duct Carcinoma", "Malignant Digestive System Neoplasm", "Pancreatic Carcinoma", "Rectal Carcinoma", "Small Intestinal Carcinoma", "Anal Carcinoma", "Digestive System Carcinoma", "Digestive System Neuroendocrine Tumor", "Pancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Acupuncture Therapy", "type": "PROCEDURE" }, { "name": "Acupressure Therapy", "type": "PROCEDURE" }, { "name": "Oral Cryotherapy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2021-06-01", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505553" }, { "nct_id": "NCT03043664", "title": "Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroenteropancreatic Neuroendocrine Tumors" ], "interventions": [ { "name": "Lanreotide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2017-07-01", "completion_date": "2022-06-07", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 2, "location_summary": "Durham, North Carolina • Columbia, South Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Columbia", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03043664" }, { "nct_id": "NCT06016855", "title": "Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Digestive System Neuroendocrine Tumor G1", "Digestive System Neuroendocrine Tumor G2", "Metastatic Digestive System Neuroendocrine Neoplasm", "Metastatic Malignant Neoplasm in the Liver", "Pancreatic Neuroendocrine Tumor G1", "Pancreatic Neuroendocrine Tumor G2" ], "interventions": [ { "name": "Tumor Debulking", "type": "PROCEDURE" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Copper Cu 64 Dotatate", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2024-05-31", "completion_date": "2028-05-28", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06016855" }, { "nct_id": "NCT01841736", "title": "Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Foregut Neuroendocrine Tumor", "Hindgut Neuroendocrine Tumor", "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Neuroendocrine Tumor", "Midgut Neuroendocrine Tumor G1", "Neuroendocrine Tumor G2", "Recurrent Digestive System Neuroendocrine Tumor G1", "Regional Digestive System Neuroendocrine Tumor G1" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2013-09-20", "completion_date": "2026-09-10", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 413, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01841736" }, { "nct_id": "NCT04090034", "title": "Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Tumors", "Gastroenteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Peptide Receptor Radionuclide Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Methodist Health System", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-03-28", "completion_date": "2026-06-28", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04090034" }, { "nct_id": "NCT05636618", "title": "Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroendocrine Tumors Unresectable", "Neuroendocrine Tumor Metastatic", "Gastroenteropancreatic Neuroendocrine Tumor", "Bronchial Neuroendocrine Tumor", "Paraganglioma", "Pheochromocytoma", "Meningioma" ], "interventions": [ { "name": "[203Pb]VMT-α-NET", "type": "DRUG" }, { "name": "[212Pb]VMT-α-NET", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Perspective Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 300, "start_date": "2023-09-27", "completion_date": "2029-12-26", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-10T23:27:36.308Z", "location_count": 19, "location_summary": "Jacksonville, Florida • Miami, Florida • Chicago, Illinois + 16 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05636618" } ] }